Metabolic Plasticity in Chemotherapy Resistance

被引:108
作者
Desbats, Maria Andrea [1 ,2 ]
Giacomini, Isabella [3 ]
Prayer-Galetti, Tommaso [4 ]
Montopoli, Monica [2 ]
机构
[1] Univ Padua, Dept Med, Padua, Italy
[2] Veneto Inst Mol Med, Padua, Italy
[3] Univ Padua, Dept Pharmaceut & Pharmacol Sci, Padua, Italy
[4] Azienda Osped Padova, UOC Urol, Padua, Italy
关键词
cancer; metabolic reprogramming; TCA cycle; Warburg effect; metabolic vulnerabilities; chemoresistance; FATTY-ACID SYNTHASE; BREAST-CANCER CELLS; PYRUVATE-DEHYDROGENASE KINASE; POTENTIAL THERAPEUTIC TARGET; MITOCHONDRIAL-DNA DEPLETION; ATP-CITRATE LYASE; OVARIAN-CANCER; PROSTATE-CANCER; DRUG-RESISTANCE; OXIDATIVE-PHOSPHORYLATION;
D O I
10.3389/fonc.2020.00281
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Resistance of cancer cells to chemotherapy is the first cause of cancer-associated death. Thus, new strategies to deal with the evasion of drug response and to improve clinical outcomes are needed. Genetic and epigenetic mechanisms associated with uncontrolled cell growth result in metabolism reprogramming. Cancer cells enhance anabolic pathways and acquire the ability to use different carbon sources besides glucose. An oxygen and nutrient-poor tumor microenvironment determines metabolic interactions among normal cells, cancer cells and the immune system giving rise to metabolically heterogeneous tumors which will partially respond to metabolic therapy. Here we go into the best-known cancer metabolic profiles and discuss several studies that reported tumors sensitization to chemotherapy by modulating metabolic pathways. Uncovering metabolic dependencies across different chemotherapy treatments could help to rationalize the use of metabolic modulators to overcome therapy resistance.
引用
收藏
页数:20
相关论文
共 340 条
[1]  
Abdel-Magid AF, 2016, ACS MED CHEM LETT, V7, P207, DOI [10.1021/acsmedchemlett.6b00016, 10.1021/acsmedchemlett.6b00259]
[2]   The Bcl-2 apoptotic switch in cancer development and therapy [J].
Adams, J. M. ;
Cory, S. .
ONCOGENE, 2007, 26 (09) :1324-1337
[3]   Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research [J].
Ahmed, Nuzhat ;
Stenvers, Kaye L. .
FRONTIERS IN ONCOLOGY, 2013, 3
[4]  
Aldossary S.A., 2019, BIOMED PHARMACOL J, V12, P07, DOI DOI 10.13005/bpj/1608
[5]   Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells [J].
Alimbetov, Dauren ;
Askarova, Sholpan ;
Umbayev, Bauyrzhan ;
Davis, Terence ;
Kipling, David .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (06)
[6]   Mitochondrial dynamics and metastasis [J].
Altieri, Dario C. .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2019, 76 (05) :827-835
[7]   Multiple blocks in the engagement of oxidative phosphorylation in putative ovarian cancer stem cells: implication for maintenance therapy with glycolysis inhibitors [J].
Alvero, Ayesha B. ;
Montagna, Michele K. ;
Sumi, Natalia J. ;
Joo, Won Duk ;
Graham, Emma ;
Mor, Gil .
ONCOTARGET, 2014, 5 (18) :8703-8715
[8]   Ovarian tumor-initiating cells display a flexible metabolism [J].
Anderson, Angela S. ;
Roberts, Paul C. ;
Frisard, Madlyn I. ;
Hulver, Matthew W. ;
Schmelz, Eva M. .
EXPERIMENTAL CELL RESEARCH, 2014, 328 (01) :44-57
[9]   Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors [J].
Andrejeva, Gabriela ;
Rathmell, Jeffrey C. .
CELL METABOLISM, 2017, 26 (01) :49-70
[10]   Antiestrogenic Effects of the Novel Sphingosine Kinase-2 Inhibitor ABC294640 [J].
Antoon, James W. ;
White, Martin D. ;
Meacham, William D. ;
Slaughter, Evelyn M. ;
Muir, Shannon E. ;
Elliott, Steven ;
Rhodes, Lyndsay V. ;
Ashe, Hasina B. ;
Wiese, Thomas E. ;
Smith, Charles D. ;
Burow, Matthew E. ;
Beckman, Barbara S. .
ENDOCRINOLOGY, 2010, 151 (11) :5124-5135